Fulcrum Therapeutics Crescita futura
Criteri Future verificati 0/6
Fulcrum Therapeutics prevede che gli utili e i ricavi cresceranno rispettivamente di 13.9% e 70.3% all'anno. Si prevede che l'EPS crescerà di 17.3% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -4.9% in 3 anni.
Informazioni chiave
13.9%
Tasso di crescita degli utili
17.26%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 18.9% |
| Tasso di crescita dei ricavi | 70.3% |
| Rendimento futuro del capitale proprio | -4.86% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 17 Aug 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento narrativa • Aug 17
FULC: Cash And Optionality Review Will Shape Post-Program Restructuring Path
Fulcrum Therapeutics' analyst fair value estimate moved from $16.75 to $4.00 as analysts cut modeled expectations following the discontinuation of pociredir in sickle cell disease and shifted focus toward the company's cash position and ongoing review of alternatives. Analyst Commentary Recent Street research on Fulcrum Therapeutics has shifted sharply following the decision to discontinue pociredir in sickle cell disease, with most firms now treating the stock as primarily a cash and optionality story rather than a late stage development story.
Aggiornamento narrativa • Aug 03
FULC: Cash-Rich Balance Sheet Will Underpin Post-Program Strategic Review Outcomes
Analysts have reset expectations on Fulcrum Therapeutics, with price targets now clustered in the $3 to $4 range. This reflects the removal of pociredir from models and a focus on the company’s cash position and ongoing review of options.Seeking Alpha • Jul 31
Fulcrum Therapeutics: Buy It For The Strategic Reset
Summary Fulcrum is trading at a deep discount due to operational distress after the suspension of their main program. But because of their fortress balance sheet, Fulcrum should have the financial strength to reset. Fulcrum is a financially strong company in operational distress, and it's trading below NCAV, making it comparable to issues that have strongly outperformed the market. Read the full article on Seeking AlphaAggiornamento narrativa • Jul 10
FULC: Cash Review And Restructuring Will Drive Future Share Repricing
Fulcrum Therapeutics' analyst fair value estimate has been revised from $25.00 to about $16.75 as analysts factor in widespread rating downgrades and sharply reduced price targets, following the discontinuation of the pociredir program in sickle cell disease and the shift toward a cash-focused review of options. Analyst Commentary Recent research on Fulcrum Therapeutics points to a broad reset in expectations after the discontinuation of pociredir in sickle cell disease, with multiple firms revising ratings and price targets, and several explicitly framing the stock more as a cash-focused situation during the current review of options.Aggiornamento narrativa • Jun 26
FULC: Cash-Rich Balance Sheet Will Shape Post-Program Review Outcome
The updated analyst price target for Fulcrum Therapeutics has shifted sharply lower, with the fair value estimate moving from about $19.00 to roughly $5.43. Analysts are factoring in the discontinuation of pociredir in sickle cell disease, class-wide safety concerns around PRC2 inhibitors, and the company's transition into a cash-focused story undergoing a review of alternatives.Articolo di analisi • Apr 01
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. By way of example, Fulcrum...Nuova narrativa • Mar 20
Fetal Hemoglobin Induction Will Reshape Sickle Cell Care And Broaden Long Term Hematology Potential
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on small molecule treatments for genetically defined diseases, with an emphasis on sickle cell disease and hematologic conditions. What are the underlying business or industry changes driving this perspective?Nuova narrativa • Mar 04
Oral Fetal Hemoglobin Induction Will Reshape Severe Sickle Cell Treatment Over The Long Term
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on developing oral fetal hemoglobin inducers for sickle cell disease and other hemoglobinopathies. What are the underlying business or industry changes driving this perspective?Articolo di analisi • Sep 25
We're Not Very Worried About Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Fulcrum Therapeutics...Articolo di analisi • Apr 04
Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Business And Shares Still Trailing The Industry
You may think that with a price-to-sales (or "P/S") ratio of 1.7x Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) is a stock...Articolo di analisi • Dec 23
There's Reason For Concern Over Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Massive 34% Price Jump
Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders have had their patience rewarded with a 34% share price jump in...Articolo di analisi • Nov 08
We Think Fulcrum Therapeutics (NASDAQ:FULC) Can Easily Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Articolo di analisi • Sep 13
Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%
Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders that were waiting for something to happen have been dealt a...Seeking Alpha • Sep 12
Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly
Summary Fulcrum Therapeutics, Inc.'s stock plummeted over 60% after its lead candidate, losmapimod, failed to meet primary and secondary endpoints in a Phase 3 study for FSHD. Despite prior optimism and significant investments from Sanofi and positive analyst ratings, the REACH trial's results were disappointing, leading to the suspension of the losmapimod program. Fulcrum's management, facing leadership changes and a challenging market, will now focus on its other clinical-stage candidate, pociredir, for sickle cell disease. With a market cap of $550m and nearly $300m in cash, the future value of Fulcrum's pipeline remains uncertain amidst intense competition. Read the full article on Seeking AlphaArticolo di analisi • Jul 12
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Fulcrum...Articolo di analisi • Feb 11
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Articolo di analisi • Oct 28
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Articolo di analisi • Jul 11
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Articolo di analisi • Nov 17
What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
The latest analyst coverage could presage a bad day for Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ), with the analysts...Articolo di analisi • Oct 18
We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 15 | -50 | -39 | -8 | 4 |
| 12/31/2027 | N/A | -39 | -38 | -14 | 5 |
| 12/31/2026 | N/A | -48 | -54 | -53 | 5 |
| 6/30/2026 | N/A | -85 | -66 | -66 | N/A |
| 3/31/2026 | N/A | -76 | -64 | -64 | N/A |
| 12/31/2025 | N/A | -75 | -60 | -60 | N/A |
| 9/30/2025 | N/A | -71 | -60 | -60 | N/A |
| 6/30/2025 | N/A | -73 | -65 | -65 | N/A |
| 3/31/2025 | 80 | -1 | 8 | 8 | N/A |
| 12/31/2024 | 80 | -10 | -2 | -2 | N/A |
| 9/30/2024 | 81 | -18 | -9 | -9 | N/A |
| 6/30/2024 | 82 | -20 | -13 | -12 | N/A |
| 3/31/2024 | 3 | -99 | -92 | -92 | N/A |
| 12/31/2023 | 3 | -97 | -91 | -91 | N/A |
| 9/30/2023 | 3 | -99 | -88 | -88 | N/A |
| 6/30/2023 | 3 | -98 | -93 | -92 | N/A |
| 3/31/2023 | 4 | -109 | -101 | -99 | N/A |
| 12/31/2022 | 6 | -110 | -99 | -97 | N/A |
| 9/30/2022 | 11 | -107 | -102 | -99 | N/A |
| 6/30/2022 | 14 | -104 | -96 | -94 | N/A |
| 3/31/2022 | 17 | -90 | -86 | -84 | N/A |
| 12/31/2021 | 19 | -81 | -80 | -78 | N/A |
| 9/30/2021 | 18 | -75 | -78 | -76 | N/A |
| 6/30/2021 | 15 | -73 | -60 | -58 | N/A |
| 3/31/2021 | 13 | -69 | -56 | -55 | N/A |
| 12/31/2020 | 9 | -71 | -55 | -54 | N/A |
| 9/30/2020 | 5 | -69 | -39 | -38 | N/A |
| 6/30/2020 | 3 | -68 | -48 | -47 | N/A |
| 3/31/2020 | 1 | -68 | N/A | -45 | N/A |
| 12/31/2019 | N/A | -90 | N/A | -39 | N/A |
| 9/30/2019 | N/A | -85 | N/A | -41 | N/A |
| 6/30/2019 | N/A | -79 | N/A | -32 | N/A |
| 3/31/2019 | N/A | -71 | N/A | -26 | N/A |
| 12/31/2018 | N/A | -39 | N/A | -23 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che FULC rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che FULC rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che FULC rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che FULC non avrà alcun fatturato il prossimo anno.
Ricavi ad alta crescita: Si prevede che FULC non avrà alcun fatturato il prossimo anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che FULC non sarà più redditizia tra 3 anni.
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/21 00:23 |
| Prezzo dell'azione a fine giornata | 2026/08/21 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Fulcrum Therapeutics, Inc. è coperta da 16 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |